BioPharma Dive 12. März 2026 Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders
BioPharma Dive 11. März 2026 FDA clears repurposed GSK drug for ultra-rare brain disease instead of autism
BioPharma Dive 10. März 2026 Xenon hits a ‘home run’ in epilepsy; FDA restarts review of Duchenne cell therapy
BioPharma Dive 9. März 2026 Bristol Myers claims success in study of another next-gen blood cancer drug
BioPharma Dive 9. März 2026 Rethinking the box: Why circular cold chain packaging is becoming a cost strategy in healthcare
BioPharma Dive 9. März 2026 Navigating the PPQ process: Proven strategies to safeguard quality for cell and gene therapies